| Literature DB >> 26966611 |
Ilaria Peluso1, Anna Raguzzini1.
Abstract
Total Antioxidant Capacity (TAC) is a biomarker often used in order to investigate oxidative stress in many pathological conditions. Saliva and urine can be collected noninvasively and represent attractive diagnostic fluids for detecting biomarkers of various pathological conditions. The reviewed case-control and intervention studies that measured salivary or urinary TAC revealed that diseases, antioxidant foods, or supplements and age, gender, and lifestyle factors influenced salivary or urinary TAC. Salivary and urinary TAC were particularly affected by oral or renal status, respectively, as well as by infection; therefore these factors must be taken into account in both case-control and intervention studies. Furthermore, some considerations on sample collection and normalization strategies could be made. In particular, unstimulated saliva could be the better approach to measure salivary TAC, whereas 24 h or spontaneous urine collection should be chosen on the basis of the study outcome and of the creatinine clearance. Finally, the uric acid-independent TAC could be the better approach to evaluate red-ox status of body, in particular after nutritional interventions and in diseases associated with hyperuricaemia.Entities:
Year: 2016 PMID: 26966611 PMCID: PMC4761395 DOI: 10.1155/2016/5480267
Source DB: PubMed Journal: Patholog Res Int ISSN: 2042-003X
Infection and oral and renal status.
| References | Case-control studies | Salivary TAC | Urinary TAC | Treatment effect |
|---|---|---|---|---|
| [ | Infection | ↓ 100% (3/3) | ↑ (100%, 2/2) | Salivary TAC |
|
| ||||
| [ | Caries | ↑ 81.2% (13/16) | Dental hygiene procedures | |
|
| ||||
| [ | Periodontitis | ↓ 66.7% (14/21) | Dental hygiene procedures or scaling and root planing | |
|
| ||||
| [ | Severe oral diseases | ↓ 66.7% (10/15) | ||
|
| ||||
| [ | Renal diseases | ↑ 50% (2/4) | ↓ 60% (3/5) | |
HAART: highly active antiretroviral therapy; TAC: total antioxidant capacity; ↑: increase; ↓: decrease; ↔: unchanged.
Systemic diseases.
| References | Case-control studies | Salivary TAC | Urinary TAC | Treatment effect |
|---|---|---|---|---|
| [ | Metabolic syndrome symptoms | ↑ 41.7% (5/12) | Salivary TAC | |
|
| ||||
| [ | Cancer | ↓ 66.7% (2/3) | ↓ 66.7% (2/3) | Salivary TAC |
|
| ||||
| [ | Neuropsychiatric disorders | ↓ 75% (3/4) | ↓ 100% (2/2) | |
|
| ||||
| [ | Congenital and genetic diseases | ↓ 33.3% (1/3) | ↓ 83.3% (5/6) | Urinary TAC: |
|
| ||||
| [ | Immune mediated and inflammatory diseases | ↓ 60% (6/10) | Salivary TAC | |
CPAP: continuous positive airway pressure; IEM: inborn errors of metabolism; NAC: N-acetylcysteine; OSAS: obstructive sleep apnea syndrome; PCI: percutaneous coronary intervention; TAC: total antioxidant capacity; TNFα: tumor necrosis factor alpha; ↑: increase; ↓: decrease; ↔: unchanged.
Nutritional and supplement interventions.
| References | Intervention | Number of bolus/repeated consumptions | Salivary TAC | Urinary TAC |
|---|---|---|---|---|
| [ | Caffeinated or alcoholic antioxidant beverages | 5/4 | ↑ 50% (2/4) | ↑ 40% (2/5) |
|
| ||||
| [ | Cocoa powder and walnuts | 2/1 | ↑ 100% (3/3) | |
|
| ||||
| [ | Fruit, juices, and vegetables | 6/3 | ↔ 100% (1/1) | ↑ 62.5% (5/8) |
|
| ||||
| [ | Supplements and supplemented foods | 4/12 | ↑ 50% (2/4) | ↑ 58.3% (7/12) |
|
| ||||
| [ | Other dietary interventions | 1/3 |
| ↑ 66.7% (2/3) |
TAC: Total Antioxidant Capacity.
Life-style factors.
| References | Factor | Salivary TAC | Urinary TAC |
|---|---|---|---|
| [ | Exercise | ↓ 75% (3/4) | ↓ 100% (1/1) |
|
| |||
| [ | Smoking habit | ↑ 20% (2/10) | ↔ 100% (1/1) |
|
| |||
| [ | Alcohol dependence | ↓ 100% (1/1) | |
|
| |||
| [ | Occupational exposure to toxicants | ↓ 100% (1/1) | ↑ 100% (1/1) |
|
| |||
| [ | Cell phone and watching TV | ↑ 75% (3/4) | |
TAC: Total Antioxidant Capacity.
Figure 1Concordat results between two different methods used in the same study to measure salivary or urinary TAC (a). Concordant results between unstimulated and stimulated saliva samples analyzed in the same study (b). References [22, 24, 34, 38, 50, 62, 64, 65, 67, 72, 78, 81, 111, 127, 135, 137, 161, 166, 175, 188–190].
Figure 2Concordant results between salivary or urinary TAC and UA levels or plasma TAC in case-control (a) or antioxidant/nutritional intervention (b) studies. References [17, 19, 21–24, 26, 28–31, 34, 37, 38, 40–44, 48–51, 55, 57, 61, 62, 65, 71, 77, 78, 81, 82, 86–89, 91, 92, 95–97, 102, 106–111, 119, 126, 132–136, 140–142, 144, 146, 147, 150, 154, 157, 159–162, 164, 166, 171, 175–178].